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ABSTRACT 
Background: Development of autonomic failure is associated with more rapid disease 
course and shorter survival in patients with Parkinson’s disease and multiple system 
atrophy. However, autonomic symptoms have not been specifically assessed as a 
prognostic factor in progressive supranuclear palsy (PSP). We evaluated whether 
development of autonomic symptoms is associated with disease progression and survival in 
PSP. 
Methods: A retrospective review of clinical data from consecutive patients with autopsy-
confirmed PSP from the Queen Square Brain Bank between January 2012 and November 
2016 was performed. Time from disease onset to four autonomic symptoms (constipation, 
urinary symptoms, erectile dysfunction and orthostatic hypotension) were noted. Time from 
diagnosis to five disease milestones and survival were calculated to assess disease 
progression and their risk was estimated through a Cox proportional hazards model.  
Results: A total of 103 PSP patients were included. Urinary symptoms and constipation 
were present in 81% and 71% of cases, respectively. Early development of constipation and 
urinary symptoms were associated with higher risk of reaching the first disease milestone 
(respectively, HR, 0.88; 95% CI, 0.83 – 0.92; p< 0.001; and HR, 0.80; 95% CI, 0.75 – 0.86; 
p< 0.001) and with a shorter survival in these patients (respectively, HR, 0.73; 95% CI, 0.64 
– 0.84; p<0.001; and HR, 0.88; 95% CI, 0.80 – 0.96; p=0.004). On multivariate analysis, 
Richardson syndrome phenotype was the other variable independently associated with 
shorter survival.  
Conclusions: Earlier urinary symptoms and constipation are associated with a more rapid 
disease progression and reduced survival in patients with PSP. 
 
Keywords: Progressive supranuclear palsy; autonomic symptoms; urinary; constipation; 
survival 
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INTRODUCTION 
Although autonomic dysfunction in Progressive Supranuclear Palsy (PSP) is not as 
severe as in Parkinson’s disease (PD) and multiple system atrophy,[1] several symptoms 
with a potential autonomic basis have been reported.[1–8] Autonomic dysfunction has been 
associated with shorter survival in multiple system atrophy (MSA),[9–12],  PD,[13] and 
possibly dementia with Lewy bodies,[14] but autonomic symptoms have not been 
systematically assessed as prognostic factors in PSP. In this study, we investigate the 
impact of development of symptoms associated with autonomic dysfunction on the clinical 
progression and survival in a large group of pathology-confirmed cases with PSP.  
 
MATERIALS AND METHODS 
Study design 
Consecutive patients between January 1st, 2012 and November 7th, 2016 with a 
pathology-confirmed diagnosis of PSP were selected from the Queen Square Brain Bank for 
Neurological Disorders (QSBB) in London, United Kingdom. Patients with comorbidities 
known to affect the autonomic nervous system (e.g., diabetic neuropathies) or insufficient 
information documenting autonomic symptoms and disease progression were excluded. The 
brain donor program was approved by a London Multi-Centre Research Ethics Committee 
and written informed consent was obtained from all donors.  
 
Clinical Assessment 
All patients were diagnosed and regularly assessed throughout their illness by 
hospital specialists (neurologists or geriatricians) in the United Kingdom. A systematic 
review of the medical records was performed by a neurologist with expertise in movement 
disorders (M.C.B.O.).  
In order to exclude potential influence of external factors (e.g., medication), 
autonomic symptoms were only documented when persisting for more than 6 months and 
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not attributed to a non-neurological cause, determined by clinical judgement. The following 
symptoms with a potential autonomic origin were noted: (1) urinary urgency, increased 
daytime frequency, and nocturia without hesitancy as defined by the International 
Continence Society;[15] (2) constipation (<3 defecations per week, having to strain to pass 
stools, or regular use of laxatives); (3) symptomatic or documented orthostatic hypotension 
(OH) defined by a greater than 20–mmHg decrease in systolic blood pressure or a greater 
than 10–mmHg decrease in diastolic blood pressure on standing; and (4) erectile 
dysfunction in males. If autonomic symptoms were not documented on medical records, they 
were considered as absent. These symptoms were selected because they are well 
documented in medical records, clinically relevant and easily assessed in clinical settings. 
Five milestones were selected to define disease progression: (1) dementia (i.e. 
cognitive impairment severe enough to significantly affect tasks of daily living); (2) 
unintelligible speech or the offering of communication aids; (3) severe dysphagia or the 
offering of percutaneous endoscopic gastrostomy; (4) dependence on wheelchair, and (5) 
placement in residential or nursing homecare. These milestones have been selected 
because they represent the different domains of impairment of functioning in PSP, including 
motor progression, cognitive impairment, and global disability.[11] They are clinically 
relevant and well documented in the medical records. 
PSP phenotype was assigned to each case, based on the predominant initial clinical 
presentation: (1) RS;[16] (2) PSP-parkinsonism (PSP-P);[16,17] (3) Pure akinesia with gait 
freezing (PAGF);[18] (4) cognitive phenotype including patients presenting with corticobasal 
syndrome (PSP-CBS);[19,20] frontal lobe cognitive or behavioural presentation (PSP-F),[21] 
and speech and language disorders (PSP-SL).[22,23] PSP-CBS, PSP-F and PSP-SL 
groups are relatively rare, and they were merged into a cognitive phenotype based on 
common neuropathological grounds (predominant cortical rather than brainstem 
involvement) in order to facilitate statistical analysis. 
Time from disease onset to development of first and each milestone, each autonomic 
symptom, diagnosis and death were calculated. 
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Control groups 
 Twenty controls without symptoms of a neurodegenerative disorder during life and no 
evidence of neuropathological condition on autopsy were selected from QSBB matched by 
gender and as closely as possible by age at death. Demographic data and autonomic 
symptoms were noted using the same criteria described for PSP patients. Data on 
autonomic symptoms and clinical progression from a group of 100 patients with pathology-
confirmed Parkinson’s disease from the QSBB were used as a disease control group. 
Further details on participant selection and assessments can be found somewhere else.[13] 
 
Neuropathological Assessment  
Formalin-fixed brain tissue samples were examined using routine stains 
supplemented by immunohistochemical analysis in representative brain regions for amyloid 
beta (Aß) peptide, hyperphosphorylated tau-protein (AT8 antibody), TDP-43, ubiquitin, and 
α-synuclein according to Queen Square Brain Bank standard protocols. Established 
pathological diagnostic criteria for PSP were used.[24]  
 
Statistical analysis 
 Clinical details were compared between PSP phenotypes, PSP versus Controls, and 
PSP versus Parkinson’s disease groups. Chi-square or Fisher exact tests for categorical 
variables, and Mann-Whitney or Kruskall-Wallis (with Dunn test for multiple comparisons) for 
continuous variables were applied as appropriate.[25] Linear regression was performed to 
assess the association of time to each autonomic symptom with clinical features. 
To visually assess the association of time from PSP onset to each autonomic 
symptom with the risk of developing a disease milestone or the risk of death (survival), 
patients were divided into 2 subgroups (e.g., early vs late) using the median value of each 
autonomic symptom, and Kaplan-Meier curves were plotted. Univariate Cox proportional 
hazards regression models were used to estimate the association between each autonomic 
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symptom with the risk of developing the first disease milestone and the risk of death. 
Multivariable Cox proportional hazards models were subsequently used and adjusted hazard 
ratios (HRs) and 95% CIs were estimated. Visual inspection of Kaplan-Meier curves and 
plots of scaled Schoenfeld residuals against time were used to assess the proportional 
hazards assumption. Censoring was considered to be uninformative.  
Statistical significance was set at P < 0.05. Statistical analyses were performed using 
the STATA statistical software, version 14 (StataCorp). 
  
RESULTS 
Demographics and clinical characteristics 
One hundred and seven PSP patients were identified within the study period. One 
patient was excluded because of insufficient clinical information and three because of 
concomitant type 2 diabetes mellitus. Main demographics and clinical data of the 103 PSP 
cases finally included in this study are shown in table 1. At least one milestone was reached 
by 102 patients (99%); with median [IQR] time from disease onset of 4.2 [2.8–5.7] years. 
Frequency and time to development of each autonomic symptom are described in Table 1 
with data on comparison between phenotype groups. Phenotype groups did not differ in 
frequency of autonomic symptoms.  
The association of autonomic symptoms to other clinical features is shown in 
Supplementary Table 1. Later development of constipation was associated with PAGF group 
(vs. RS, p<.001, linear regression). Earlier urinary symptoms and erectile dysfunction were 
associated with RS phenotype (vs. PSP-P, p<.001 and p=.04, respectively, linear 
regression) and with older age at onset (p<.001 and p=.005, respectively, linear regression).  
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Table 1: Comparison of clinical features and number of patients and time (years) to reach 
disease milestones and autonomic symptoms between PSP phenotype groups 
 RS (n=53) 
PSP-P (n= 
23) PAGF (n=5) 
Cognitive (n= 
22) Total (n=103) 
p Value 
Number of 
females (%) 22 (42%) 5 (22%) 4 (80%) 8 (36%) 39 (38%) 
NS* 
Age at onset 
66.8 [63.9–
72.8] 
66.3 [56.6–
72.8] 
69.1 [61.9–
74.0] 
65.9 [61.3–
72.6] 
66.8 [62.1–
72.5] 
NS 
Age at death 
74.3 [70.8–
81.0] 
76.5 [67.3–
82.9] 
82.7 [75.8–
84.6] 
74.7 [68.0–
81.1] 
74.6 [70.4–
81.4] 
NS 
Disease 
duration 7.0 [5.5–8.4] 
9.0 [7.0–
13.2] 
13.6 [8.3–
16.3] 7.6 [5.6–9.6] 
7.5 [5.7–
10.0] 
p=.002a, p=.003b, 
p=.05c, p=.02d 
Time to 
diagnosis 2.3 [1.5–3.8] 5.2 [2.5–7.0] 3.0 [2.4–7.8] 3.3 [2.0–5.3] 3.1 [1.8–5.0] 
p<.001a, p=.03e 
Time to falls 
n= 53 
(100%) 
n= 23 
(100%) n= 5 (100%) n= 22 (100%) 
n= 103 
(100%) 
- 
0.4 [0–1.8] 3.0 [1.0–5.0] 2.0 [0.2–5.7] 2.3 [0.5–4.0] 1.0 [0–3.3] 
p<.001a, p<.001e 
 
Time to first 
milestone 
n= 53 
(100%) n= 22 (96%) n=5 (100%) n= 22 (100%) 
n= 102 
(99%) 
NS* 
4.1 [2.6–5.0] 5.3 [3.5–9.1] 
5.6 [5.3–
12.5] 3.3 [2.3–5.1] 4.2 [2.8–5.7] 
p=.01a, p=.004b, 
p=.01c, p=.003d,  
 
Time to 
Wheelchair 
n= 47 (89%) n= 19 (83%) n= 5 (100%) n=21 (95%) n= 92 (89%) 
NS* 
4.7 [4.0–5.7] 7.0 [4.1–9.6] 
6.1 [5.3–
12.5] 5.0 [3.6–8.8] 5.0 [4.0–7.1] 
p=.02a, p=.01b, 
p=.04d 
Time to 
Dysarthria 
n= 40 (75%) n= 16 (70%) n= 3 (60%) n= 17 (81%) n= 76 (74%) 
NS* 
5.7 [4.0–6.6] 
7.3 [5.7–
12.2] 
8.5 [5.5–
15.0] 6.0 [4.3–7.4] 6.0 [4.3–7.4] 
p=.003a, p=.04b, 
p=.03c 
Time to 
Dysphagia 
n= 38 (73%) n= 16 (70%) n= 2 (40%) n= 14 (64%) n=70 (69%) 
NS* 
6.2 [4.7–7.6] 
8.1 [5.8–
11.8] 
15.9 [15.1–
16.8] 6.5 [4.9–8.4] 6.9 [5.1–8.6] 
p=.008a, p=.004b, 
p=.01d 
Time to 
Dementia 
n= 18 (34%) n= 13 (57%) n= 2 (40%) n= 16 (73%) n= 49 (48%) 
p=.01* 
3.4 [1.8–4.4] 
6.0 [3.5–
11.3] 
11.6 [9.2–
13.9] 3.2 [2.2–5.1] 3.7 [2.3–6.8] 
p=.01a, p=.01b, 
p=.02c, p=.01d 
Time to Care 
n= 46 (87%) n= 20 (87%) n= 3 (60%) n= 20 (91%) n= 89 (86%) NS
* 
5.0 [3.3–6.6] 
6.8 [4.0–
10.1] 
13.7 [13.0–
15.0] 5.6 [3.7–8.8] 5.6 [3.9–7.8] 
p=.04a, p=.001b, 
p=.005d, p=.01f 
 
Time to 
Constipation 
n= 38 (72%) n= 14 (61%) n= 5 (100%) n= 16 (73%) n= 73 (71%) NS
* 
4.1 [2.9–6.2] 4.8 [3.6–6.1] 
11.7 [6.9–
12.5] 4.7 [2.7–6.8] 4.8 [3.4–6.7] 
p=.001b, p=.006d, 
p=.009f 
Time to 
Urinary 
symptoms 
n= 43 (81%) n= 18 (78%) n= 3 (60%) n= 19 (86%) n= 83 (81%) NS
* 
2.7 [1.7–5.0] 5.4 [2.2–9.8] 
4.0 [3.0–
11.7] 4.3 [3.2–6.3] 4.0 [2.0–6.1] 
p=.006a, p=.03e 
Time to 
Erectile 
dysfunction 
(n= 64) 
n=10 (32%) n= 7 (39%) n= 1 (100%) n= 2 (14%) n= 20 (31%) 
NS* 
-2.0 [-7.4–
0.8] 2.5 [0.6–5.8] 1.0 0.1 [-0.4–0.6] 0.4 [-3.0–2.6] 
NS 
Time to 
Orthostatic 
Hypotension 
n= 2 (4%) n= 5 (22%) n= 0 n= 2 (9%) n= 9 (9%) 
NS* 
2.5 [2.0–3.1] 4.0 [0.5–5.7] - -0.1 [-2.0–1.8] 2.0 [0.5–4.0] 
NS 
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Table 1 legend: Data are expressed as number (frequency) or median [interquartile range] 
NS= Non-significant. RS= Richardson syndrome; PSP-P= PSP-parkinsonism; PAGF= Pure 
Akinesia with Gait Freezing. Cognitive group is a composite of PSP-Speech/Language, 
PSP- Frontal/behavioural and PSP-Corticobasal Syndrome groups. 
Kruskall-Wallis comparison between groups and Dunn multiple comparisons test: aRS vs. 
PSP-P; bRS vs. PAGF; cCognitive vs. PSP-P; dCognitive vs. PAGF; eRS vs. Cognitive; fPSP-
P vs. PAGF. *Fisher exact test.  
 
 
Comparison of autonomic symptoms with controls and Parkinson’s disease patients 
 As some of the autonomic symptoms are common in older individuals, 
findings of PSP were compared with those of healthy controls. PSP patients had a higher 
frequency of all four autonomic symptoms (Supplementary Table 2) which could not be 
explained by additional neurodegenerative changes in the PSP group as both had similar 
concomitant neuropathological findings (Supplementary Table 3). When compared to 
Parkinson’s disease (as a disease control with known autonomic dysfunction), PSP patients 
had less constipation and orthostatic hypotension, but did not differ in urinary symptoms and 
erectile dysfunction frequencies (Supplementary Table 2).  
 
Association of autonomic symptoms with disease progression 
Earlier development of constipation and urinary symptoms were associated with a 
significantly increased risk of reaching the first milestone (HR for constipation, 0.88; 95% CI, 
0.83 – 0.92; p<.001; and HR for urinary symptoms, 0.80; 95% CI, 0.75 – 0.86; p<.001). 
Orthostatic hypotension did not affect the risk of reaching the first milestone; early erectile 
dysfunction increased the risk of reaching the first milestone, although this was not 
statistically significant (Table 2 and Figure 1). 
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Table 2: Cox Proportional Hazards Regression Models of Clinical Features for First 
Milestone and Survival 
 
Autonomic symptoms HR (95% CI) p Value 
First milestone 
Constipation 0.88 (0.83 – 0.92) <.001 
Urinary symptoms 0.80 (0.75 – 0.86) <.001 
Erectile dysfunction 0.92 (0.84 – 1.01) .07 
Orthostatic hypotension 0.86 (0.67 – 1.13) .29 
Survival 
Constipation 0.80 (0.75 – 0.86) <.001 
Urinary symptoms 0.86 (0.81 – 0.91) <.001 
Erectile dysfunction 0.93 (0.84 – 1.02) .13 
Orthostatic hypotension 1.00 (0.79 – 1.27) .98 
 
Table 2 legend: HR= Hazard ratio. The different forms of the main explanatory variables 
were considered in turn in different Cox proportional hazards regression models (not in the 
same model). 
 
 
Association of autonomic symptoms with survival 
 Earlier development of constipation was associated with shorter survival (HR, 0.80; 
95% CI 0.75 – 0.86; p<.001), as was earlier development of urinary symptoms (HR, 0.86; 
95% CI 0.81 – 0.91; p<.001). Early erectile dysfunction or orthostatic hypotension did not 
significantly influence survival risk (Table 2 and Figure 2). 
 
Other determinants of survival and multivariable analysis of survival predictors 
Older age at onset, shorter time to falls and PSP phenotype, together with 
constipation and urinary symptoms, showed an association with survival and were used as 
explanatory variables in the multivariate Cox regression model (Table 3, Supplementary 
Figure1). Early constipation remained significantly associated with a 27% increase of risk of 
death per year after adjustment (HR, 0.73; 95% CI, 0.64 – 0.84; p<.001). Association 
between early urinary symptoms and shorter survival also remained significant, with a 12% 
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increase of risk of death per year (HR, 0.88; 95% CI, 0.80 – 0.96; p=.004). RS phenotype 
was the only other variable to maintain significance after multivariable analysis. (Table 3) 
 
Table 3: Multivariable analysis of survival predictors 
 
 Crude HR (95% CI) p Value Adjusted HR (95% 
CI) 
p Value 
Time to constipation (y) 0.85 (0.75 – 0.86) <.001 0.73 (0.64 – 0.84) <.001 
Time to urinary symptoms (y) 0.86 (0.81 – 0.91) <.001 0.88 (0.80 – 0.96) .004 
Male gender 1.23 (0.82 – 1.85) .32 1.76 (0.93 – 3.31) .08 
Age at onset (y) 1.05 (1.02 – 1.07) <.001 0.99 (0.95 – 1.04) .74 
Time to falls (y) 0.86 (0.78 – 0.95) .002 0.94 (0.77 – 1.14) .51 
PSP phenotype     
PSP-P (vs. RS) 0.36 (0.21 – 0.63) <.001 0.20 (0.07 – 0.57) .003 
PAGF (vs. RS) 0.23 (0.09 – 0.61) .003 0.22 (0.03 – 1.55) .13 
Cognitive (vs. RS) 0.74 (0.45 – 1.23) .25 0.93 (0.44 – 2.00) .86 
 
Table 3 legend: HR= Hazard ratio; RS= Richardson syndrome; PSP-P= PSP-parkinsonism; 
PAGF= Pure akinesia with gait freezing. Cognitive group is a composite of PSP-
Speech/Language, PSP- Frontal/behavioural and PSP- Corticobasal Syndrome groups. 
 
 
DISCUSSION 
Although previous studies have shown association of urinary incontinence with 
shorter survival in PSP,[21,26] this is the first study to systematically assess autonomic 
symptoms as predictors of disease course and mortality in a large group of autopsy-
confirmed PSP patients. Our findings showed that earlier development of constipation and 
urinary symptoms are significantly associated with more rapid disease progression and 
shorter survival. There is no association between the development of first milestone or death 
with orthostatic hypotension or erectile dysfunction, in contrast to MSA.[10] 
One of the strengths of our study is that all patients had pathologically confirmed 
diagnosis, since it is conceivable that patients with parkinsonism and autonomic symptoms 
may be misdiagnosed with MSA and, therefore, clinical studies can underestimate the actual 
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prevalence and impact of autonomic symptoms in PSP. For example, six of our 103 patients 
(5.8%) had received a clinical diagnosis of MSA in life. Another study demonstrated a high 
prevalence of PSP cases with autonomic failure that were misdiagnosed in life as MSA.[27]  
Prevalence of Autonomic symptoms: Autonomic symptoms tend to be more common 
in the elderly; for example, the prevalence of constipation lies around 33.5% in people aged 
60-101.[28] Although not the primary aim of this study, the fact that all four autonomic 
symptoms were observed more frequently in PSP than in healthy controls suggests they 
could not be explained solely by autonomic dysfunction associated with age or additional 
concomitant neuropathologies in the PSP group. Except for OH, prevalence of all autonomic 
symptoms was similar to patients with Parkinson’s disease. This is in keeping with other 
studies comparing both pathologies.[1–8] All together our findings suggest that there is an 
element of clinically relevant disturbance in most areas of autonomic function in PSP.  
Autonomic symptoms and survival. The main finding of our study is that early 
development of constipation and urinary symptoms was associated with rapid development 
of disease milestones and shorter survival after adjustment for relevant variables. 
Classically, this more rapid course has been attributed in synucleinopathies to a more 
aggressive underlying neurodegenerative process although a recent clinicopathological 
study on Parkinson’s disease failed to show any association between autonomic dysfunction 
and histological staging.[13] 
Selective involvement of autonomic regulatory structures of the brainstem, spinal 
cord and hypothalamus has been proposed as the pathological substrate for autonomic 
dysfunction and poor prognosis in patients with MSA.[12,29] A previous neuropathological 
study of PSP demonstrated tau pathology in selected brainstem nuclei involved in autonomic 
control, with a role in regulating cardiovascular function and micturition networks. This is a 
possible explanation for some of these autonomic symptoms in PSP, although it failed to 
show any correlation with disease duration.[30] Another study described  tau deposition in 
the Onuf’s nucleus, the structure responsible for bladder and sphincter control, in PSP 
patients with urinary symptoms and abnormality of sphincter muscles on 
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electromyography.[31] In addition, because cortico-subcortical structures are responsible for 
voluntary control of micturition,[2] earlier urinary incontinence could reflect widespread 
involvement of the frontal lobe, although urinary symptoms were not associated with 
cognitive phenotypes in our study. 
Autonomic dysfunction in PSP is not well understood, and although preganglionic 
involvement of central nervous system areas has been shown in neuropathological 
studies,[30,31] postganglionic involvement of nervous structures and other factors such as 
age, medications, immobility or dietary and water intake [32] could potentially influence the 
presence and severity of some of the autonomic symptoms assessed in our study. We 
would like to emphasise that in this study we assessed autonomic symptoms (rather than 
autonomic function) and that, although we tried to limit the influence of other non-
neurological factors with strict inclusion criteria, we acknowledge that some of these 
symptoms may have a multifactorial origin. Our study was conducted using routinely 
collected clinical information on autonomic symptoms and we are unable to make any firm 
conclusions whether these symptoms are the result of dysautonomia due to direct 
involvement by the neurodegenerative process or secondary to the combination with other 
external factors. However, these results on PSP are in contrast with a similar study 
performed on PD, where every autonomic symptom was associated with a more rapid 
disease progression and reduced survival.[13] 
We found that constipation and urinary symptoms, but not OH and erectile 
dysfunction, showed a significant prognostic value in our patients. In addition, different PSP 
phenotypes have not shown specific predilection for autonomic regulatory structures 
suggesting that the reported worse prognosis in PSP might not be due to global 
dysautonomia secondary to neuropathological involvement of autonomic structures and 
additional factors may influence this association. The selective influence of some of the 
autonomic symptoms on prognosis may be due to intrinsic morbidities and mortality 
associated with them (e.g. urinary symptoms may predispose patients to development of 
urinary infections).  
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Other predictors of survival. Several articles have described natural history and 
predictors of survival in PSP with conflicting results which may be partially explained by 
heterogeneity in the methodology. The most consistent predictors of survival appear to be 
RS phenotype,[11,33] early dysphagia,[21,26,34,35] early cognitive symptoms,[21,35] early 
falls,[21,26,36] and severity of disease measured by the PSP rating scale.[37,38] In our 
study, we found that older age at onset, shorter time to falls and RS and cognitive 
phenotypes were all associated with shorter survival, but only RS phenotype, in addition to 
development of constipation and urinary symptoms, remained significant after adjustment in 
multivariable analysis. It is possible that factors associated with RS phenotype are 
contributory to the shorter survival as this phenotype is associated with earlier falls.  
The fact that RS and cognitive phenotypes are associated with shorter survival in 
comparison with PSP-P and PAGF (Supplementary Figure1) is in keeping with studies 
showing an inverse relationship between total tau burden and disease duration in PSP 
phenotypes.[39]  For instance, PSP-P and PAGF phenotypes have less tau burden 
compared with PSP-RS and also have longer survival duration.[18,40] Additionally, despite a 
shift of tau burden from deep grey matter structures towards the cortical regions in PSP-CBS 
compared with PSP-RS, the overall tau burden and survival period are similar between 
these two phenotypes.[20] 
 Limitations. The retrospective nature of this study, with clinical assessments 
performed by different professionals with various levels of clinical expertise, without 
methodological homogeneity and the lack of confirmation with neurophysiologic 
cardiovascular autonomic testing are inherent limitations in clinicopathological studies using 
brain bank archival collection. This may have led to underreporting of autonomic symptoms, 
particularly in healthy controls, who may have not been as closely monitored as 
parkinsonian patients. Nevertheless, only patients regularly seen by hospital specialists 
throughout their disease (or general practitioners in the case of controls) with regular 
documentation were included in the study, and only autonomic symptoms with relevance to 
clinical practice were assessed to minimize documentation bias. Moreover, as health care is 
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free to access in the United Kingdom, controls included in the study had regular contact with 
primary care as part of public health and preventive medicine policies, which may have 
mitigated any potential surveillance bias. Despite the limitation of patients not having been 
assessed with neurophysiologic testing, the fact that the autonomic symptoms were clinically 
assessed means the results can be generalized to clinical practice where autonomic function 
tests are not always available. Although the merging of PSP-CBS, PSP-F and PSP-SL to 
facilitate statistical analysis into a cognitive group based on the predominant cortical 
involvement may limit the interpretation of the results of PSP subtype comparisons, it has no 
effect at all on the primary conclusions of the study. Brain bank studies tend to include more 
severe or atypical cases, which may account for some differences with clinical studies.  
 In conclusion, this study found that early onset of constipation and urinary symptoms 
is associated with more rapid disease progression and shorter survival. Constipation and 
urinary symptoms are common in PSP and increasing awareness and recognition in clinical 
settings will contribute to the improvement of patient counselling. These findings may also 
have important clinical implications as a more optimal management of autonomic 
dysfunction could potentially improve the prognosis on these patients. Further prospective 
studies assessing autonomic symptoms with pathological confirmation of the diagnosis are 
warranted to corroborate our findings. 
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LEGENDS TO FIGURES 
 
Figure 1: Kaplan-Meier curves of cumulative risk of first disease milestone amongst patients 
with PSP by time to development of each autonomic symptom (Early vs Late) 
 
Figure 2: Kaplan-Meier curves of survival probability among patients with PSP by time to 
development of each autonomic symptom (Early vs Late) 
 
